Teva's immune disorder drug meets main goal in mid-stage trial
- Posted on September 2, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Teva's immune disorder drug meets main goal in mid-stage trial
Sept 2 (Reuters) - Israeli drugmaker Teva Pharmaceutical Industries said on Wednesday its experimental drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of a mid-stage trial. U.S.-listed shares of the company were up over 4% in premarket trading. • Celiac disease is an autoimmune condition in which gluten triggers an immune response that
